45 – Healthcare Providers and Services, and Healthcare Technology
45 – Healthcare Providers and Services, and Healthcare Technology
45 – Healthcare Providers and Services, and Healthcare Technology
Transform your PDFs into Flipbooks and boost your revenue!
Leverage SEO-optimized Flipbooks, powerful backlinks, and multimedia content to professionally showcase your products and significantly increase your reach.
This table shows a list of topics identified as relevant by different stakeholder groups. They can be considered as stakeholders’ suggestions or requests<br />
for topics to be monitored or disclosed by organizations.<br />
Additional information about the project can be found at https://www.globalreporting.org/reporting/sector-guidance/Topics-<br />
Research/Pages/default.aspx<br />
<strong>45</strong> <strong>–</strong> <strong>Healthcare</strong> <strong>Providers</strong> <strong>and</strong> <strong>Services</strong>, <strong>and</strong> <strong>Healthcare</strong> <strong>Technology</strong><br />
21 Topics<br />
<strong>Providers</strong> of patient health care services. Includes dialysis centers, lab testing services, <strong>and</strong> pharmacy management services. Also includes<br />
companies providing business support services to health care providers, such as clerical support services, collection agency services, staffing<br />
services <strong>and</strong> outsourced sales & marketing services. Owners <strong>and</strong> operators of health care facilities, including hospitals, nursing homes,<br />
rehabilitation centers <strong>and</strong> animal hospitals. Owners <strong>and</strong> operators of Health Maintenance Organizations (HMOs) <strong>and</strong> other managed plans.<br />
Companies providing information technology services primarily to health care providers. Includes companies providing application, systems<br />
<strong>and</strong>/or data processing software, internet-based tools, <strong>and</strong> IT consulting services to doctors, hospitals or businesses operating primarily in the<br />
health care sector. Distributors <strong>and</strong> wholesalers of health care products not included elsewhere.<br />
Sustainability<br />
Category<br />
Environmental<br />
Topic<br />
Toxic chemicals<br />
<strong>and</strong> materials<br />
Topic<br />
Specification<br />
(if available)<br />
Hazardous<br />
chemical <strong>and</strong><br />
toxin use<br />
Explanation Reference(s) 1 Constituency<br />
Health care facilities around the world are reducing their<br />
use of hazardous chemicals <strong>and</strong> products. For example:<br />
More than 6,000 health care facilities in the U.S. are<br />
eliminating mercury-containing medical devices in favor<br />
of safer non-mercury alternatives<br />
Hospitals from Stockholm, to Prague, <strong>and</strong> throughout the<br />
U.S. are phasing out phthalate-containing PVC medical<br />
devices <strong>and</strong> switching to safer plastics<br />
232, 496 Business<br />
Sustainability Topics for Sectors: What do stakeholders want to know?<br />
HEALTHCARE PROVIDERS AND SERVICES, AND HEALTHCARE TECHNOLOGY<br />
May 2013<br />
Page 1 of 26
Sustainability<br />
Category<br />
Topic<br />
Topic<br />
Specification<br />
(if available)<br />
Explanation Reference(s) 1 Constituency<br />
Many hospitals are reducing pesticides by using<br />
integrated pest management techniques<br />
Many hospitals are choosing safer, less toxic building<br />
materials for new construction <strong>and</strong> renovation projects.<br />
Green chemistry is the design of products <strong>and</strong> processes<br />
that reduce or eliminate the use <strong>and</strong> generation of<br />
hazardous substances. Green chemistry seeks to reduce<br />
<strong>and</strong> prevent pollution at its source.<br />
High-priority chemicals <strong>and</strong> materials include:<br />
Mercury<br />
PVC (vinyl plastic) <strong>and</strong> phthalates<br />
Brominated flame retardants<br />
Glutaraldehyde <strong>and</strong> ethylene oxide<br />
Pesticides<br />
Volatile organic compounds in building materials<br />
Hazardous ingredients in cleaning products.<br />
Green chemistry is the design of products <strong>and</strong> processes<br />
that reduce or eliminate the use <strong>and</strong> generation of<br />
hazardous substances. Green chemistry seeks to reduce<br />
<strong>and</strong> prevent pollution at its source.<br />
The ubiquitous exposure to toxic chemicals in everyday<br />
life has increasingly become a health concern.<br />
Unfortunately, many products used in health care<br />
contribute to hazardous exposures — including cleaners<br />
<strong>and</strong> disinfectants, phthalates in medical devices, flame<br />
retardants in furniture, formaldehyde in furniture <strong>and</strong><br />
solvents in labs.<br />
Emerging scientific research is raising the level of<br />
Sustainability Topics for Sectors: What do stakeholders want to know?<br />
HEALTHCARE PROVIDERS AND SERVICES, AND HEALTHCARE TECHNOLOGY<br />
May 2013<br />
Page 2 of 26
Sustainability<br />
Category<br />
Topic<br />
Topic<br />
Specification<br />
(if available)<br />
Explanation Reference(s) 1 Constituency<br />
concern about the health impacts of chronic chemical<br />
exposures. We now know that: Even small doses of<br />
chemicals can cause disease — interfering with sexual<br />
development, disrupting hormones <strong>and</strong> causing cancer at<br />
very low levels. Children <strong>and</strong> developing babies are most<br />
vulnerable. Hundreds of synthetic chemicals are found in<br />
human breast milk <strong>and</strong> in the cord blood of babies in the<br />
womb. Chemicals can act like drugs in our body,<br />
disrupting systems at low levels of exposure, <strong>and</strong><br />
potentially causing harm in combination.<br />
Chemical Related Diseases: As chemical use has grown in<br />
industrialized societies, so have chemical-related<br />
diseases, including cancer, asthma, birth defects,<br />
developmental disabilities, autism, endometriosis <strong>and</strong><br />
infertility. Mounting scientific evidence links the<br />
incidence of these diseases in part to environmental<br />
toxicants. Health care institutions have a particular<br />
ethical responsibility to use products containing<br />
chemicals that pose less risk to human health — <strong>and</strong> due<br />
to their massive buying power, the health care system<br />
can play a key role in shifting the economy toward green<br />
chemistry.<br />
A growing number of hospitals are taking a "better safe<br />
than sorry" approach to chemicals — eliminating<br />
suspected hazards <strong>and</strong> switching to safer alternatives.<br />
Benefits of this approach to the bottom line can include<br />
reduced disposal costs, reduced liability <strong>and</strong> improved<br />
health for employees.<br />
Sustainability Topics for Sectors: What do stakeholders want to know?<br />
HEALTHCARE PROVIDERS AND SERVICES, AND HEALTHCARE TECHNOLOGY<br />
May 2013<br />
Page 3 of 26
Sustainability<br />
Category<br />
Topic<br />
Topic<br />
Specification<br />
(if available)<br />
Explanation Reference(s) 1 Constituency<br />
Toxins with an especially heavy impact in the health care<br />
sector may be found in:<br />
489 Business<br />
Cleaners <strong>and</strong> disinfectants<br />
Dioxin-containing byproducts<br />
Electronic equipment<br />
Flame retardants<br />
Fragrance chemicals<br />
Mercury-containing medical devices <strong>and</strong> wastes<br />
Pesticides<br />
Phthalates <strong>and</strong> DEHP<br />
PVC<br />
Health care institutions, like institutions outside the<br />
health care sector, regularly use a surprising number of<br />
highly toxic materials. These toxins affect patients,<br />
hospital staff, <strong>and</strong> hospital visitors.<br />
Plastics use <strong>and</strong><br />
management<br />
Many of these toxins are defined <strong>and</strong> regulated by<br />
federal, state <strong>and</strong> local laws. Others are used daily but<br />
hardly regulated at all. They include carcinogens,<br />
materials that damage the skin <strong>and</strong> organs, <strong>and</strong> materials<br />
that corrode, irritate, or release other toxins in the<br />
course of normal use, storage, transportation or disposal.<br />
Plastic, a valuable material, can generate significant<br />
positive, or negative, impacts on economy, environment<br />
<strong>and</strong> society. Plastic should be treated as a resource <strong>and</strong><br />
managed judiciously.<br />
A disclosure on management approach for plastics,<br />
353, 367 Civil Society<br />
Organization<br />
Sustainability Topics for Sectors: What do stakeholders want to know?<br />
HEALTHCARE PROVIDERS AND SERVICES, AND HEALTHCARE TECHNOLOGY<br />
May 2013<br />
Page 4 of 26
Sustainability<br />
Category<br />
Topic<br />
Topic<br />
Specification<br />
(if available)<br />
Explanation Reference(s) 1 Constituency<br />
including governance, strategy, risks, opportunities,<br />
considering: opportunities for product redesign,<br />
increasing recycled content, implementing reclaim<br />
<strong>and</strong>/or reuse which could attract economies, br<strong>and</strong><br />
loyalty, investment, employee goodwill, <strong>and</strong>; risks to the<br />
business, stakeholder health, environment <strong>and</strong> society<br />
(including reputational/social license to operate,<br />
regulatory, investor, insurer, <strong>and</strong> liability risks) for<br />
plastics that are directly harmful to stakeholders, or<br />
indirectly through plastics being wasted/littered.<br />
Performance indicators regarding the types <strong>and</strong> volumes<br />
of plastics being used, collected <strong>and</strong>/or distributed<br />
downstream; the portion that is made of post-consumerrecycled,<br />
bio-based, biodegradable, compostable, <strong>and</strong>/or<br />
oxobiodegradable material; the ratio of expected lifespan<br />
of plastic products/packaging in contrast to the<br />
duration of their intended use; these volumes broken<br />
down by end of life disposition.<br />
Most of this disclosure can be captured through the<br />
existing GRI framework (e.g. GRI G3 EC9, EN1, EN2,<br />
EN22), but commentary is needed to ensure disclosers<br />
appreciate the materiality of plastic; other questions can<br />
be added to the framework. Refer to the Plastic<br />
Disclosure Project ( www.plasticdisclosure.org ) for more<br />
details on the suggested questions. PDP will align its<br />
questions to GRI G4 to assist disclosers.<br />
Plastic are in high use in these "activity groups", <strong>and</strong> can<br />
have significant positive, or negative, impacts on the<br />
economy, environment <strong>and</strong> society: Economics: There<br />
Sustainability Topics for Sectors: What do stakeholders want to know?<br />
HEALTHCARE PROVIDERS AND SERVICES, AND HEALTHCARE TECHNOLOGY<br />
May 2013<br />
Page 5 of 26
Sustainability<br />
Category<br />
Topic<br />
Topic<br />
Specification<br />
(if available)<br />
Explanation Reference(s) 1 Constituency<br />
are significant cost savings available to organisations that<br />
treat plastic as a resource (e.g. through redesign, use of<br />
recycled content, reclaiming, etc.) <strong>and</strong> risks of increased<br />
direct costs (regulation, liability, cost of capital,<br />
insurance) to organisations that do not lead in this area<br />
as well as indirect economic costs to impacted industries<br />
(e.g. food production, tourism). Environment: Plastics<br />
that are wasted or littered become extremely harmful to<br />
the environment, which will have a material effect on<br />
biodiversity <strong>and</strong> the global food chain, both nearby <strong>and</strong><br />
far outside the local area of operations. Society: Some<br />
plastics are harmful to stakeholders during manufacture,<br />
use <strong>and</strong>/or disposal (e.g. due to phthalates, BPA), impact<br />
the wellbeing of society (e.g. effect of litter on<br />
community spirit <strong>and</strong> their interest in sustainability).<br />
While a valuable invention, which benefits society in<br />
many ways, the negative impacts associated with<br />
society's growing use of plastic are not fully recognised.<br />
Roughly 85% of plastic used in products <strong>and</strong> packaging is<br />
not recycled, <strong>and</strong> most plastic produced in the last 60<br />
years still remains in the environment today. Discarded<br />
plastics persist in the environment for dozens or<br />
hundreds of years, accumulating across the globe, often<br />
out of sight of the producers <strong>and</strong> users. The direct<br />
physical impacts of plastic are significant to the<br />
organisation in increased costs or missed opportunities,<br />
<strong>and</strong> related economies (e.g. over $1.2bn in annual<br />
damages to ocean-related industries in Asia-Pacific), the<br />
environment through harming habitats <strong>and</strong> species, <strong>and</strong><br />
Sustainability Topics for Sectors: What do stakeholders want to know?<br />
HEALTHCARE PROVIDERS AND SERVICES, AND HEALTHCARE TECHNOLOGY<br />
May 2013<br />
Page 6 of 26
Sustainability<br />
Category<br />
Topic<br />
<strong>Healthcare</strong><br />
waste<br />
management<br />
Topic<br />
Specification<br />
(if available)<br />
<strong>Healthcare</strong>,<br />
medical<br />
research<br />
facilities <strong>and</strong><br />
laboratories<br />
Explanation Reference(s) 1 Constituency<br />
to stakeholders health when exposed to the chemical<br />
ingredients; <strong>and</strong> are magnified if fragmentation of the<br />
plastic occurs, making it available for ingestion to<br />
additional species, who adsorb the chemical ingredients<br />
<strong>and</strong>/or the toxins carried on the plastic. These negative<br />
impacts could be avoided <strong>and</strong> turned into positive<br />
impacts, if plastic was treated as a resource to be<br />
managed judiciously (e.g. the US economy lost $8.3bn<br />
worth of plastic packaging in 2010) - "It is not good<br />
business practice to throw away valuable resources".<br />
Medical waste is all waste materials generated at health<br />
care facilities, such as hospitals, clinics, physician's<br />
offices, dental practices, blood banks, <strong>and</strong> veterinary<br />
hospitals/clinics, as well as medical research facilities <strong>and</strong><br />
laboratories.<br />
102, 242 Business<br />
The Medical Waste tracking Act of 1988 defines medical<br />
waste as "any solid waste that is generated in the<br />
diagnosis, treatment, or immunization of human beings<br />
or animals, in research pertaining thereto, or in the<br />
production or testing of biologicals." This definition<br />
includes, but is not limited to:<br />
blood-soaked b<strong>and</strong>ages<br />
culture dishes <strong>and</strong> other glassware<br />
discarded surgical gloves<br />
discarded surgical instruments<br />
discarded needles used to give shots or draw blood<br />
(e.g., medical sharps)<br />
cultures, stocks, swabs used to inoculate cultures<br />
Sustainability Topics for Sectors: What do stakeholders want to know?<br />
HEALTHCARE PROVIDERS AND SERVICES, AND HEALTHCARE TECHNOLOGY<br />
May 2013<br />
Page 7 of 26
Sustainability<br />
Category<br />
Topic<br />
Topic<br />
Specification<br />
(if available)<br />
Explanation Reference(s) 1 Constituency<br />
removed body organs (e.g., tonsils, appendices, limbs)<br />
discarded lancets<br />
Hospitals generate millions of tons of waste each year. In<br />
the past, many hospitals simply dumped all waste<br />
streams together, from reception-area trash to<br />
operating-room waste, <strong>and</strong> burned them in incinerators<br />
— <strong>and</strong> this is still common practice in many developing<br />
countries.<br />
Infectious waste<br />
Yet medical waste incineration is a leading source of<br />
dioxin, mercury, lead <strong>and</strong> other dangerous pollutants<br />
that threaten human health <strong>and</strong> the environment.<br />
Despite these dangers, many governments, public health<br />
agencies, international organizations <strong>and</strong> transnational<br />
corporations continue to promote incineration<br />
technologies as waste management "solutions."<br />
Infectious waste is waste that is suspected to contain<br />
pathogens (disease-causing bacteria, viruses, parasites,<br />
or fungi) in sufficient concentration or quantity to cause<br />
disease in susceptible hosts. The subcategories of<br />
infectious waste are (a) waste contaminated with blood<br />
or other body fluids; (b) microbiological cultures <strong>and</strong><br />
stocks of infectious agents from laboratory work; <strong>and</strong> (c)<br />
waste from infected patients in isolation wards. Waste<br />
contaminated with blood or other body fluids include:<br />
free-flowing blood, blood components, <strong>and</strong> other body<br />
fluids (semen, vaginal secretions, cerebrospinal fluid,<br />
synovial fluid, pleural fluid, pericardial fluid, peritoneal<br />
527 Civil Society<br />
Organization<br />
Sustainability Topics for Sectors: What do stakeholders want to know?<br />
HEALTHCARE PROVIDERS AND SERVICES, AND HEALTHCARE TECHNOLOGY<br />
May 2013<br />
Page 8 of 26
Sustainability<br />
Category<br />
Topic<br />
Topic<br />
Specification<br />
(if available)<br />
Explanation Reference(s) 1 Constituency<br />
fluid, amniotic fluid, saliva <strong>and</strong> other body fluids visibly<br />
contaminated with blood); dressings, b<strong>and</strong>ages, swabs,<br />
gloves, masks, gowns, drapes, <strong>and</strong> other material<br />
contaminated with blood or other body fluids; <strong>and</strong> waste<br />
that has been in contact with the blood of patients<br />
undergoing hemodialysis (e.g. dialysis equipment such as<br />
tubing <strong>and</strong> filters, disposable towels, gowns, aprons,<br />
gloves, <strong>and</strong> laboratory coats).<br />
With regards to infectious healthcare waste, there are<br />
four approaches to healthcare waste treatment. A<br />
decentralized approach is one where the technology is<br />
installed on-site at the healthcare facility. By treating the<br />
waste as close as possible to the point of generation, this<br />
approach has the advantage of eliminating the transport<br />
of hazardous healthcare waste.<br />
Another approach is centralized treatment at an off-site<br />
facility designed to h<strong>and</strong>le the waste from hospitals,<br />
clinics, medical laboratories, doctors‘ offices, <strong>and</strong> other<br />
health facilities in a large urban center, province, or<br />
region. This approach requires the transport of infectious<br />
waste from many sources to the central treatment<br />
facility <strong>and</strong> is only possible if there is a good<br />
infrastructure for collection, transport <strong>and</strong> temporary<br />
storage. Its major benefit is cost reduction as it takes<br />
advantage of the economies of scale.<br />
A third approach is cluster treatment wherein a hospital<br />
serves as a hub for treating waste from surrounding<br />
nearby hospitals, clinics, <strong>and</strong> other facilities. Cluster<br />
treatment is an option for small municipalities, parts of a<br />
Sustainability Topics for Sectors: What do stakeholders want to know?<br />
HEALTHCARE PROVIDERS AND SERVICES, AND HEALTHCARE TECHNOLOGY<br />
May 2013<br />
Page 9 of 26
Sustainability<br />
Category<br />
Topic<br />
Topic<br />
Specification<br />
(if available)<br />
Explanation Reference(s) 1 Constituency<br />
province, or districts that may be too far from a central<br />
treatment facility but have an adequate infrastructure<br />
for collection <strong>and</strong> transport of infectious waste within<br />
their area.<br />
A fourth approach is mobile treatment. In this approach,<br />
the treatment technology is mounted on a mobile<br />
platform, such as a specially designed mobile container<br />
or a flatbed truck, <strong>and</strong> is brought to hospitals <strong>and</strong> other<br />
health facilities within a service territory. The mobile<br />
treatment system treats <strong>and</strong> converts infectious waste<br />
into regular waste as the mobile unit is parked on the<br />
hospital grounds. After treatment, the system is driven<br />
to the next healthcare facility.<br />
Pharmaceutical<br />
products <strong>and</strong><br />
items for<br />
h<strong>and</strong>ling them<br />
Improper treatment <strong>and</strong> disposal of healthcare waste<br />
pose serious hazards of disease transmission due to<br />
exposures to infectious agents among waste pickers,<br />
waste workers, health workers, patients, <strong>and</strong> the<br />
community in general.<br />
For a healthcare facility, several practical options exist<br />
for small quantities of pharmaceutical waste: return of<br />
expired pharmaceuticals to the donor or manufacturer;<br />
encapsulation <strong>and</strong> burial in a sanitary l<strong>and</strong>fill; chemical<br />
decomposition in accordance with the manufacturer‘s<br />
recommendations if chemical expertise <strong>and</strong> materials are<br />
available; <strong>and</strong> dilution in large amounts of water <strong>and</strong><br />
sewer discharge into a sewer for moderate quantities of<br />
relatively mild liquid or semi-liquid pharmaceuticals, such<br />
as solutions containing vitamins, cough syrups,<br />
intravenous solutions <strong>and</strong> eye drops.<br />
527 Civil Society<br />
Organization<br />
Sustainability Topics for Sectors: What do stakeholders want to know?<br />
HEALTHCARE PROVIDERS AND SERVICES, AND HEALTHCARE TECHNOLOGY<br />
May 2013<br />
Page 10 of 26
Sustainability<br />
Category<br />
Topic<br />
Topic<br />
Specification<br />
(if available)<br />
Explanation Reference(s) 1 Constituency<br />
Pharmaceutical waste includes expired, unused, spilled,<br />
<strong>and</strong> contaminated pharmaceutical products, drugs,<br />
vaccines, <strong>and</strong> sera that are no longer needed. The<br />
classification also includes discarded items used in the<br />
h<strong>and</strong>ling of pharmaceuticals, such as bottles, boxes,<br />
gloves, masks, vials, <strong>and</strong> tubing contaminated with<br />
pharmaceutical residues.<br />
Improper treatment <strong>and</strong> disposal of pharmaceutical<br />
healthcare waste pose risks, because for example waste<br />
scavengers might collect the expired, unused, spilled,<br />
<strong>and</strong> contaminated pharmaceutical products, drugs,<br />
vaccines, <strong>and</strong> sera that are no longer needed, <strong>and</strong> take or<br />
sell them.<br />
The huge quantities of medicines ending up in waste or<br />
in aquatic systems are a major environmental health<br />
issue. The increasing documentation of low-dose health<br />
effects makes pharmaceuticals a priority area from an<br />
environmental health perspective. Hundreds of different<br />
active pharmaceutical compounds are being discovered<br />
in waterways all over the world. Concern is increasing<br />
about the harm these might be doing to human health<br />
<strong>and</strong> the environment.<br />
44, 240 Business<br />
Although levels are usually too low to result in acute<br />
effects such as organ damage, there are two cases where<br />
drugs have had drastic effects: where the antiinflammatory<br />
diclofenac has virtually wiped out the<br />
vulture population of Asia, while man-made estradiol has<br />
Sustainability Topics for Sectors: What do stakeholders want to know?<br />
HEALTHCARE PROVIDERS AND SERVICES, AND HEALTHCARE TECHNOLOGY<br />
May 2013<br />
Page 11 of 26
Sustainability<br />
Category<br />
Topic<br />
Topic<br />
Specification<br />
(if available)<br />
Explanation Reference(s) 1 Constituency<br />
caused fish to start changing sex.<br />
Although the levels of other drugs don't cause acute<br />
reactions, there is little or no information about the nonacute<br />
effects which low doses might have on wildlife <strong>and</strong><br />
humans.<br />
There are suggestions in research that contaminated<br />
water affects fish in subtle ways, such as changing<br />
breeding behaviour. This may cause declines in<br />
populations, or even be an indicator of other problems.<br />
Ordinary risk assessment is of limited value in<br />
determining the environmental hazard posed by low<br />
levels of pharmaceutical compounds, as it only looks at<br />
acute effects, struggles to assess the potential effects of<br />
mixtures of compounds, <strong>and</strong> has no way to anticipate<br />
freak reactions.<br />
What we do know is that pharmaceutical compounds are<br />
biologically active <strong>and</strong> they are detectable in our<br />
waterways. We can be sure that it would be better if<br />
they were not there. Therefore, we need to take steps to<br />
deal with the problem.<br />
While patients should be allowed access to the best<br />
available pharmaceutical treatment, other things being<br />
equal, we should consider the medicine's PBT<br />
(persistence, bioaccumulation <strong>and</strong> toxicity) when<br />
developing, manufacturing, prescribing, purchasing,<br />
Sustainability Topics for Sectors: What do stakeholders want to know?<br />
HEALTHCARE PROVIDERS AND SERVICES, AND HEALTHCARE TECHNOLOGY<br />
May 2013<br />
Page 12 of 26
Sustainability<br />
Category<br />
Topic<br />
Topic<br />
Specification<br />
(if available)<br />
<strong>Technology</strong> for<br />
waste<br />
sterilization<br />
<strong>and</strong>/or<br />
destruction<br />
Explanation Reference(s) 1 Constituency<br />
donating <strong>and</strong> disposing of medicines. Our collective aim<br />
should be to protect people <strong>and</strong> the environment from<br />
contamination of hazardous chemicals that wouldn't<br />
otherwise be there.<br />
A wide range of alternative technologies are now<br />
commercially available. Steam sterilization in autoclaves<br />
is the most common alternative treatment method.<br />
Since autoclaves have been used in the treatment of<br />
infectious waste for many decades, their operation is<br />
well established. Several types of steam sterilizers or<br />
autoclaves are available: gravity-fed, pre-vacuum <strong>and</strong><br />
pulse or multivacuum cycle autoclaves. Unlike<br />
incinerators, autoclaves heat the waste to temperatures<br />
high enough to disinfect but not hot enough to burn <strong>and</strong><br />
create air pollutants such as dioxins <strong>and</strong> furans. A posttreatment<br />
shredder or grinder could be used if the waste<br />
is to be rendered unrecognizable <strong>and</strong> if reduction of<br />
waste volume is desired. Microwave treatment is<br />
another type of alternative technology. For years, the<br />
most common microwave device has been a medium- to<br />
large-scale, semi-continuous system using an internal<br />
shredder, rotating internal screw, <strong>and</strong> industrial<br />
magnetrons to generate microwave energy. There are<br />
also commercial dry heat treatment technologies. Moist<br />
heat has been shown to be more effective than dry heat<br />
in achieving disinfection, so dry heat systems generally<br />
require longer exposure times <strong>and</strong> higher temperatures<br />
to meet minimum disinfection levels.<br />
123, 241 Business<br />
Medical waste incineration is a leading source of dioxin<br />
Sustainability Topics for Sectors: What do stakeholders want to know?<br />
HEALTHCARE PROVIDERS AND SERVICES, AND HEALTHCARE TECHNOLOGY<br />
May 2013<br />
Page 13 of 26
Sustainability<br />
Category<br />
Topic<br />
Topic<br />
Specification<br />
(if available)<br />
Explanation Reference(s) 1 Constituency<br />
pollution, one of the most potent carcinogens known to<br />
science. Fortunately, there are viable alternatives to<br />
incineration that are safer, cleaner, do not produce<br />
dioxin, <strong>and</strong> are just as effective at disinfecting medical<br />
waste. These technologies can be used on all types of<br />
medical waste, including pathological <strong>and</strong> chemotherapy<br />
waste.<br />
Given that alternatives to incineration are available, a<br />
complete phase-out of medical waste incineration is<br />
possible <strong>and</strong> appropriate. This will require changes in<br />
state laws, persuasion of hospital systems that non-burn<br />
approaches are both effective <strong>and</strong> environmentally<br />
preferable, public education, <strong>and</strong> better segregation <strong>and</strong><br />
reduction of waste by hospitals. Pathological <strong>and</strong><br />
chemotherapeutic wastes can be treated using alkaline<br />
hydrolysis technology which combines steam sterilization<br />
with tissue digestion using sodium or potassium<br />
hydroxide.<br />
Investment <strong>and</strong> commitment in the management of<br />
health care waste (a by-product of healthcare that<br />
includes sharps, non-sharps, blood, body parts,<br />
chemicals, pharmaceuticals, medical devices <strong>and</strong><br />
radioactive materials).<br />
4<strong>45</strong> Mediating<br />
Institution<br />
Poor management of health care waste potentially<br />
exposes health care workers, waste h<strong>and</strong>lers, patients<br />
<strong>and</strong> the community at large to infection, toxic effects <strong>and</strong><br />
injuries, <strong>and</strong> risks polluting the environment.<br />
<strong>Healthcare</strong> waste is a by-product of healthcare that<br />
includes sharps, non-sharps, blood, body parts,<br />
593 Mediating<br />
Institution<br />
Sustainability Topics for Sectors: What do stakeholders want to know?<br />
HEALTHCARE PROVIDERS AND SERVICES, AND HEALTHCARE TECHNOLOGY<br />
May 2013<br />
Page 14 of 26
Sustainability<br />
Category<br />
Topic<br />
Topic<br />
Specification<br />
(if available)<br />
Explanation Reference(s) 1 Constituency<br />
chemicals, pharmaceuticals, medical devices <strong>and</strong><br />
radioactive materials<br />
Social Migrant workers Recruitment<br />
<strong>and</strong><br />
employment<br />
Poor management of healthcare waste exposes<br />
healthcare workers, waste h<strong>and</strong>lers <strong>and</strong> the community<br />
to infections, toxic effects <strong>and</strong> injuries<br />
Recruitment <strong>and</strong> employment of migrant workers<br />
Number of migrant workers employed<br />
Countries of origin<br />
Gender of workers<br />
Positions within company<br />
Length of contracts<br />
Recruitment channels<br />
Any fees for recruitment<br />
Passport retention<br />
Migrant workers both internal <strong>and</strong> external are a<br />
significant <strong>and</strong> growing feature of all company activities.<br />
There are over 200 million migrants in the world. They<br />
are found within nearly all business sectors <strong>and</strong> across all<br />
regions. Many migrant workers, particularly those<br />
working in unskilled jobs are subject to discrimination<br />
<strong>and</strong> are vulnerable to exploitation <strong>and</strong> abuse.<br />
For many migrants exploitation begins during<br />
recruitment. Exorbitant fees <strong>and</strong> other charges, often at<br />
usurious rates of interest can leave many migrant<br />
workers effectively bonded labour whatever the<br />
subsequent conditions of employment.<br />
253 Mediating<br />
Institution<br />
Sustainability Topics for Sectors: What do stakeholders want to know?<br />
HEALTHCARE PROVIDERS AND SERVICES, AND HEALTHCARE TECHNOLOGY<br />
May 2013<br />
Page 15 of 26
Sustainability<br />
Category<br />
Topic<br />
Privacy of<br />
medical records<br />
<strong>and</strong> genetic data<br />
Topic<br />
Specification<br />
(if available)<br />
Explanation Reference(s) 1 Constituency<br />
Company due diligence <strong>and</strong> reporting should therefore<br />
extend into the supply chain for labour.<br />
The storage <strong>and</strong> uses made of health records <strong>and</strong> the<br />
results of genetic tests raise questions in relation to the<br />
right to privacy.<br />
66 Mediating<br />
Institution<br />
Access to quality<br />
medical<br />
treatments<br />
Care quality<br />
Racial <strong>and</strong><br />
ethnic<br />
disparities<br />
Staff training,<br />
staffing ratios<br />
per patient <strong>and</strong><br />
turnover rates<br />
This case raises questions about the right to privacy of<br />
the people from whom the samples were taken. There<br />
has, for example, been concern that samples of this kind<br />
could be used in paternity suits or to assess health<br />
insurance risks. AT the other h<strong>and</strong>, Retention of the<br />
samples has significant potential public health benefits,<br />
such as retrospective diagnosis from the stored blood<br />
spot, even after the individual is deceased, to help<br />
provide counselling to the family. Approved research can<br />
provide information that is of public health interest or<br />
information that can provide a better underst<strong>and</strong>ing on<br />
how diseases develop, identifying potential opportunities<br />
for intervention.<br />
Measures taken to eliminate racial <strong>and</strong> ethnic disparities<br />
in providing treatments.<br />
Minorities can be treated in a disadvantageous way in<br />
health care as in all other areas in life<br />
Adequate <strong>and</strong> properly trained staff are critical to<br />
healthcare, oil <strong>and</strong> gas <strong>and</strong> financial services.<br />
<strong>Healthcare</strong> providers, including hospitals, nursing homes<br />
<strong>and</strong> home health care need to report on staffing ratios<br />
per patient <strong>and</strong> their turn-over rates. This information<br />
494 Business<br />
2<strong>45</strong>, 362 Labor<br />
Sustainability Topics for Sectors: What do stakeholders want to know?<br />
HEALTHCARE PROVIDERS AND SERVICES, AND HEALTHCARE TECHNOLOGY<br />
May 2013<br />
Page 16 of 26
Sustainability<br />
Category<br />
Topic<br />
Topic<br />
Specification<br />
(if available)<br />
Explanation Reference(s) 1 Constituency<br />
directly indicates the quality of care provided.<br />
with the Volker rule (US Dodd-Frank) are critical to<br />
solvency.<br />
Clinical trials<br />
Disease spread<br />
control<br />
Food quality<br />
Consent<br />
processes<br />
Health care<br />
facilities<br />
Catering<br />
services<br />
Extensive academic research <strong>and</strong> judicial decisions as<br />
well as federal <strong>and</strong> state legislation make these material<br />
indicators for sustainability. See, for example, "Hospital<br />
Nurse Staffing <strong>and</strong> Patient Mortality, Nurse Burnout, <strong>and</strong><br />
Job Dissatisfaction," JAMA. 2002; 288(16):1987-1993.<br />
doi:10.1001/jama.288.16.1987;<br />
Article 7 states that “no one shall be subjected without<br />
his free consent to medical <strong>and</strong> scientific<br />
experimentation”. Several companies <strong>and</strong> research<br />
bodies have faced media <strong>and</strong> legal scrutiny over consent<br />
processes used in clinical trials, irrespective of their<br />
medical success or failure<br />
Acute respiratory diseases during health care may<br />
constitute a public health emergency of international<br />
concern as defined in the International Health<br />
Regulations<br />
<strong>Healthcare</strong> providers should take into account the<br />
following topics when designing the menu for their<br />
patients:<br />
* Antibiotics<br />
*Chemicals in the food system<br />
Genetically engineered foods<br />
*greening serviceware<br />
*hospital food environments<br />
*climate change (by buying local products for example)<br />
66 Mediating<br />
Institution<br />
583, 586 Civil Society<br />
Organization<br />
357 Business<br />
Sustainability Topics for Sectors: What do stakeholders want to know?<br />
HEALTHCARE PROVIDERS AND SERVICES, AND HEALTHCARE TECHNOLOGY<br />
May 2013<br />
Page 17 of 26
Sustainability<br />
Category<br />
Topic<br />
Health service<br />
effectiveness<br />
Topic<br />
Specification<br />
(if available)<br />
Cost<br />
effectiveness of<br />
key health<br />
interventions<br />
Explanation Reference(s) 1 Constituency<br />
Health care facilities across the continent are<br />
recognizing that the food system — how our food is<br />
produced <strong>and</strong> distributed — is misaligned with dietary<br />
guidelines, <strong>and</strong> is largely reliant on methods of<br />
production <strong>and</strong> distribution that harm public <strong>and</strong><br />
environmental health.<br />
The food system is inherently a deeply complex <strong>and</strong><br />
interwoven concept that must be considered from an<br />
integrative, ecological perspective in order to develop<br />
solutions that nourish our health <strong>and</strong> that of the planet.<br />
Healthy Food in Health Care has selected a broadreaching<br />
scope of topics of concern that form the basis<br />
for our work. These issues, like antibiotic resistance, for<br />
example, cut to the core of a hospital’s operations.<br />
Others, like climate change <strong>and</strong> genetically engineered<br />
foods, are matters of serious public health concern that<br />
we believe the health care community has a capacity <strong>and</strong><br />
power to influence.<br />
Some systems devote resources to expensive<br />
interventions with small effects on population health,<br />
while at the same time low cost interventions with<br />
potentially greater benefits are not fully implemented.<br />
The impact of interventions on population health is vital.<br />
But it is also important to determine the role of different<br />
interventions in contributing to other socially desirable<br />
goals, such as reducing health inequalities, <strong>and</strong> being<br />
responsive to the legitimate expectations of the<br />
population<br />
584 Mediating<br />
Institution<br />
The impact of interventions on population health is vital.<br />
Sustainability Topics for Sectors: What do stakeholders want to know?<br />
HEALTHCARE PROVIDERS AND SERVICES, AND HEALTHCARE TECHNOLOGY<br />
May 2013<br />
Page 18 of 26
Sustainability<br />
Category<br />
Topic<br />
Medicines<br />
management<br />
Topic<br />
Specification<br />
(if available)<br />
Patient safety<br />
<strong>and</strong><br />
environmental<br />
impacts<br />
Explanation Reference(s) 1 Constituency<br />
But it is also important to determine the role of different<br />
interventions in contributing to other socially desirable<br />
goals, such as reducing health inequalities, <strong>and</strong> being<br />
responsive to the legitimate expectations of the<br />
population<br />
Rational use of medicines requires that "patients receive<br />
medications appropriate to their clinical needs, in doses<br />
that meet their own individual requirements, for an<br />
adequate period of time, <strong>and</strong> at the lowest cost to them<br />
<strong>and</strong> their community<br />
590 Mediating<br />
Institution<br />
Corruption<br />
Access to <strong>and</strong><br />
quality of<br />
treatments<br />
Irrational use of medicines is a major problem<br />
worldwide. WHO estimates that more than half of all<br />
medicines are prescribed, dispensed or sold<br />
inappropriately, <strong>and</strong> that half of all patients fail to take<br />
them correctly. The overuse, underuse or misuse of<br />
medicines results in wastage of scarce resources <strong>and</strong><br />
widespread health hazards<br />
Measures taken to avoid corruption in the following<br />
processes: provision of services by medical personnel,<br />
human resources management, drug selection <strong>and</strong> use,<br />
procurement of drugs <strong>and</strong> medical equipment,<br />
distribution <strong>and</strong> storage of drugs, regulatory systems,<br />
<strong>and</strong> budgeting <strong>and</strong> pricing<br />
505, 555 Business<br />
Because of the complexity of health care systems <strong>and</strong><br />
services, <strong>and</strong> the significant amount of money involved,<br />
the risk of corruption is high, that can result in the<br />
inequality of access to <strong>and</strong> quality of treatments.<br />
Sustainability Topics for Sectors: What do stakeholders want to know?<br />
HEALTHCARE PROVIDERS AND SERVICES, AND HEALTHCARE TECHNOLOGY<br />
May 2013<br />
Page 19 of 26
Sustainability<br />
Category<br />
Other<br />
Topic<br />
Corporate<br />
governance<br />
Topic<br />
Specification<br />
(if available)<br />
<strong>Healthcare</strong><br />
systems <strong>and</strong><br />
services<br />
Gender<br />
participation on<br />
governance<br />
bodies<br />
Explanation Reference(s) 1 Constituency<br />
Corruption in hospitals, informal payments for health<br />
care, in pharmaceutical sector <strong>and</strong> HIV/AIDS<br />
Fighting corruption in the health sector is a complex<br />
challenge. At one end of the scale are doctors <strong>and</strong> nurses<br />
who charge small informal payments to patients to<br />
supplement inadequate incomes. At the other end, <strong>and</strong><br />
far more pernicious, are the corrupt suppliers who offer<br />
bribes, <strong>and</strong> the health ministers <strong>and</strong> hospital<br />
administrators who accept bribes, or siphon millions of<br />
dollars from health budgets, skewing health policy <strong>and</strong><br />
depleting funds that should be spent building hospitals,<br />
buying medicines or employing staff.<br />
GOVERNANCE / EUROPE: boardroom lady boom: is it<br />
possible without quotas?<br />
On 22 June, the CapitalCom agency published its 2011<br />
survey into the boardroom gender mix of CAC 40<br />
companies, with fairly encouraging results: the<br />
proportion of women on the board has doubled in recent<br />
years, from 10.5% in 2009 to 20.8% in 2011.<br />
34, 506 Civil Society<br />
Organization<br />
389 Financial<br />
Markets &<br />
Information<br />
Users<br />
In January, the French parliament adopted legislation<br />
imposing quotas for the proportion of women on the<br />
board of major companies. Under the measures, the<br />
development of female board membership is m<strong>and</strong>atory<br />
<strong>and</strong> gradual: 20% for listed groups, public companies of<br />
an administrative, industrial <strong>and</strong> commercial nature by<br />
January 2014, rising to 40% by January 2017. The law<br />
also stipulates that companies with no women present<br />
on their board must appoint at least one within six<br />
Sustainability Topics for Sectors: What do stakeholders want to know?<br />
HEALTHCARE PROVIDERS AND SERVICES, AND HEALTHCARE TECHNOLOGY<br />
May 2013<br />
Page 20 of 26
Sustainability<br />
Category<br />
Topic<br />
Topic<br />
Specification<br />
(if available)<br />
Explanation Reference(s) 1 Constituency<br />
months of it being on the statute books (voted on 13<br />
January 2011). In France, some 2,000 companies are<br />
affected (the 650 largest listed firms <strong>and</strong> companies with<br />
more than 500 employees <strong>and</strong> those generating sales in<br />
excess of €50bn). In terms of sanctions for<br />
noncompliance, appointments that run counter to the<br />
parity principles are to be declared null <strong>and</strong> void <strong>and</strong><br />
attendance fees are to be temporarily suspended.<br />
At the European level <strong>and</strong> at the instigation of the Vicepresident<br />
of the European Commission, Viviane Reding,<br />
the European parliament will decide in March 2012 on<br />
whether to adopt common legislation on this matter (a<br />
m<strong>and</strong>atory proportion of women in decision-making<br />
positions of 30% in 2015 <strong>and</strong> 40% in 2020). This will<br />
depend on the level of improvement seen based on the<br />
selfregulation of European companies, in accordance<br />
with the equality initiative adopted by the European<br />
Commission in December 2010 <strong>and</strong> the European<br />
parliament resolution of 17 January 2008 calling for the<br />
Commission <strong>and</strong> member states to promote a balance<br />
between women <strong>and</strong> men on company boards,<br />
particularly where member states are shareholders.<br />
Europe as a whole illustrates the degree of hesitation<br />
between a soft-law approach <strong>and</strong> conventional<br />
legislation (quotas in this instance), but it is clear from<br />
the experience at national level that the second method<br />
tends to get much better results.<br />
Sustainability Topics for Sectors: What do stakeholders want to know?<br />
HEALTHCARE PROVIDERS AND SERVICES, AND HEALTHCARE TECHNOLOGY<br />
May 2013<br />
Page 21 of 26
Sustainability<br />
Category<br />
Topic<br />
Political<br />
accountability<br />
Topic<br />
Specification<br />
(if available)<br />
Explanation Reference(s) 1 Constituency<br />
There are various measures of political accountability<br />
that can be measured (contributions, disclosure, board<br />
oversight).<br />
Note that this topic is applicable to more than the three<br />
industries noted. Essentially the political accountability<br />
practices of any company that is owned by public<br />
stockholders. Political contributions, the amount of<br />
disclosure <strong>and</strong> board oversight are among the data items<br />
that would be helpful in a sustainability report.<br />
394, 616 Financial<br />
Markets &<br />
Information<br />
Users<br />
In making investment decisions (especially for investors<br />
interested in socially responsible investing) is would be<br />
helpful to underst<strong>and</strong> how a given company is exposed<br />
to political risk (i.e. are they backing the winning<br />
c<strong>and</strong>idate, are they subject to potential retribution, why<br />
do they find it necessary to make political contributions,<br />
etc.).<br />
I have found the information I reference to be helpful in<br />
constructing investment portfolios that take into account<br />
this attribute of sustainability. Since it is not currently an<br />
established parameter in the socially responsible<br />
investment industry (www.ussif.org), adoption by the<br />
Global Reporting Initiative would go a long way in<br />
moving the topic of political accountability forward.<br />
Sustainability Topics for Sectors: What do stakeholders want to know?<br />
HEALTHCARE PROVIDERS AND SERVICES, AND HEALTHCARE TECHNOLOGY<br />
May 2013<br />
Page 22 of 26
Sustainability<br />
Category<br />
Topic<br />
Public health<br />
service<br />
effectiveness<br />
Topic<br />
Specification<br />
(if available)<br />
Laboratory<br />
readiness -<br />
Outbreaks of<br />
novel, emerging<br />
<strong>and</strong> dangerous<br />
pathogens<br />
Explanation Reference(s) 1 Constituency<br />
Laboratories readiness <strong>and</strong> response for rapid detection<br />
<strong>and</strong> containment of outbreaks of emerging <strong>and</strong><br />
dangerous pathogens<br />
Outbreaks of emerging <strong>and</strong> dangerous pathogens are a<br />
great risk for public health<br />
591 Mediating<br />
Institution<br />
1<br />
All references can be found at https://www.globalreporting.org/reporting/sector-guidance/Topics-Research/Pages/default.aspx<br />
Sustainability Topics for Sectors: What do stakeholders want to know?<br />
HEALTHCARE PROVIDERS AND SERVICES, AND HEALTHCARE TECHNOLOGY<br />
May 2013<br />
Page 23 of 26
References<br />
All references can be found at https://www.globalreporting.org/reporting/sector-guidance/Topics-Research/Pages/default.aspx<br />
34<br />
Baghdadi-Sabeti, G. & Serhan, F., 2010. WHO Good Governance for Medicines Programme: An Innovative Approach to Prevent Corruption in the<br />
Pharmaceutical Sector, Geneva: World Health Organization (WHO).<br />
44 Becker, J., 2010. Minding the Gap: Research Priorities to Address Pharmaceuticals in the Environment, Arlington: Health Care Without Harm.<br />
66<br />
Castan Centre for Human Rights Law; International Business Leaders Forum; Office of the United Nations High Commissioner for Human Rights,<br />
2008. Human Rights Translated, A Business Reference Guide, New York: United Nations Global Compact.<br />
102 Davis, S. C., 2002. 10 Ways to reduce regulated medical wastes (RMW), Arlington: <strong>Healthcare</strong> without Harm.<br />
123<br />
232<br />
240<br />
Emmanuel, J. & Stringer, R., 2007. For Proper Disposal: A global inventory of alternative medical waste treatment technologies, Arlington:<br />
Health Care without harm.<br />
Greiner, T., Rossi, M., Thorpe, B. & Kerr, B., 2006. Healthy Business Strategies for Transforming the Toxic Chemical Economy, Spring Brook:<br />
Clean Production Action.<br />
Health Care Without Harm Europe, 2007. Preventing damage to the environment from pharmaceuticals: a primer, Prague: Health Care Without<br />
Harm Europe.<br />
241 Health Care Without Harm, 2001. Non-Incineration Medical Waste Treatment Facilities, Washington, D.C.: Health Care Without Harm.<br />
242<br />
Health Care Without Harm, 2001. Waste Minimization, Segregation <strong>and</strong> Recycling in Hospitals. [Online]<br />
Available at: http://www.noharm.org/lib/downloads/waste/Waste_Min_Seg_Recyc_in_Hosp.pdf,<br />
[Accessed 19 March 2013].<br />
2<strong>45</strong> Heineman, B. J., 2011. We May Never Know Leaders' Responsibility in Gulf Disaster, Boston: Harvard Business Review.<br />
253 Institute for Human Rights <strong>and</strong> Business (IHRB), 'The Dhaka Principles for Migration with Dignity', Dhaka, 2011.<br />
Sustainability Topics for Sectors: What do stakeholders want to know?<br />
HEALTHCARE PROVIDERS AND SERVICES, AND HEALTHCARE TECHNOLOGY<br />
May 2013<br />
Page 24 of 26
353<br />
Kershaw, P., Katsuhiko, S., Lee, S., Samseth, J., Woodring, D., & Smith, J., 2011. Plastic Debris in the Ocean. In United Nations Environment<br />
Programme (UNEP), UNEP Year Book 2011 (pp. 20-33). Nairobi: United Nations Early Warning <strong>and</strong> Assessment.<br />
357 Kulick, M., Nathanson, A. & Sirois, E., 2011. Menu of Change: Healthy food in health care, Arlington: Health Care Without Harm.<br />
362<br />
Aiken, L.H., Clarke, S.P., Sloane, D.M., Sochalski, J., Silber, J.H., 20025. Hospital Nurse Staffing <strong>and</strong> Patient Mortality, Nurse Burnout, <strong>and</strong> Job<br />
Dissatisfaction. Journal of the American Medical Association, 288(16), pp. 1987-1993.<br />
367 MacKerron, C., 2011. Unfinished Business: The Case for Extended Producer Responsibility for Post-Consumer Packaging, Oakl<strong>and</strong>: As You Sow.<br />
389° Natixis, 2011. Strategy Note Equity Research - Strategy/SRI: Monthly review June 2011, Paris: Natixis.<br />
394 Nowak, T., 2012. Low Fee Socially Responsible Investing. 1st ed. Grayslake: Quantum Financial Planning LLC.<br />
4<strong>45</strong><br />
489<br />
494<br />
496<br />
Prüss, A., Giroult, E. & Rushbrook, P., 1999. Safe Management of Wastes from Health-care Activities, Geneva: World Health Organization<br />
(WHO).<br />
Sutherl<strong>and</strong>, L., Easthope, T., Sattler, B., Welker-Hood, K., Wilburn, S., 2008. Guide to Choosing Safer Products <strong>and</strong> Chemicals, Arlington: Health<br />
Care Without Harm.<br />
The American Hospital Association (AHA), 2012. Eliminating Racial <strong>and</strong> Ethnic Disparities. [Online]<br />
Available at: http://www.aha.org/advocacy-issues/disparities/index.shtml<br />
[Accessed 29 March 2013].<br />
The Centers for Occupational <strong>and</strong> Environmental Health, University of California, 2008. Green Chemistry: Cornerstone to a Sustainable<br />
California, San Francisco: The Centers for Occupational <strong>and</strong> Environmental Health, University of California.<br />
505 Transparency International, 2006. Global Corruption Report 2006, London: Transparency International.<br />
506 Transparency International, 2006. Global Corruption Report 2006: Corruption <strong>and</strong> Health, London: Pluto Press.<br />
527<br />
United Nations Environment Programme (UNEP), 2012. Compendium of Technologies for Treatment/Destruction of <strong>Healthcare</strong> Waste, Nairobi:<br />
United Nations Environment Programme (UNEP).<br />
555 Vian, T. & Nordberg, C., 2008. Corruption in the Health Sector, Bergen: U4 - Chr. Michelsen Institute.<br />
Sustainability Topics for Sectors: What do stakeholders want to know?<br />
HEALTHCARE PROVIDERS AND SERVICES, AND HEALTHCARE TECHNOLOGY<br />
May 2013<br />
Page 25 of 26
583 World Health Organization (WHO), 2002. Prevention of Hospital-acquired Infections, Geneva: World Health Organization (WHO).<br />
584 World Health Organization (WHO), 2003. WHO Guide to cost-effectiveness analysis, Geneva: World Health Organization (WHO).<br />
586<br />
590<br />
World Health Organization (WHO), 2007. Infection Prevention <strong>and</strong> Control of Epidemic- <strong>and</strong> P<strong>and</strong>emic-prone Acute Respiratory Diseases in<br />
Health Care, Geneva: World Health Organization (WHO).<br />
World Health Organization (WHO), 2012. Pursuit of Responsible Use of Medicines: Sharing <strong>and</strong> Learning from Country Experiences, Geneva:<br />
World Health Organization (WHO).<br />
591 World Health Organization (WHO), 2012. Rapid Risk Assessment of Acute Public Health Events, Geneva: World Health Organization (WHO).<br />
593<br />
616<br />
World Health Organization (WHO), Department for Public Health <strong>and</strong> Environment Assessing <strong>and</strong> Managing Environmental Risks to Health,<br />
'WHO Core Principles for Achieving Safe <strong>and</strong> Sustainable Management of Health-care Waste', 2007.<br />
Zicklin Center for Business Ethics at the Wharton School of the University of Pennsylvania, 2012. CPA-Zicklin Index of Corporate Political<br />
Accountability <strong>and</strong> Disclosure, Washington, D.C.: Center for Political Accountability.<br />
° Resource available on request <strong>and</strong>/or for a fee.<br />
Sustainability Topics for Sectors: What do stakeholders want to know?<br />
HEALTHCARE PROVIDERS AND SERVICES, AND HEALTHCARE TECHNOLOGY<br />
May 2013<br />
Page 26 of 26